COPDおよび喘息用デバイスの市場規模、シェア、成長分析：製品別、適応症別、流通チャネル別、地域別 - 産業予測 2025～2032年

COPDおよび喘息用デバイスの世界市場規模は、2023年に487億8,000万米ドルと評価され、2024年の511億7,000万米ドルから2032年には750億3,000万米ドルに成長し、予測期間（2025～2032年）のCAGRは4.9％で成長する見通しです。

肺薬物送達デバイス市場は、慢性閉塞性肺疾患（COPD）や喘息の有病率の増加、技術の進歩、高齢者人口の増加などを背景に増加傾向にあります。COPDは気流の閉塞を特徴とし、息切れや慢性の咳などの症状があり、喘息は気道機能の低下と呼吸困難が特徴で、効果的な吸入療法が必要です。これらのデバイスは、薬液をエアロゾル化粒子に変換し、これらの慢性症状を管理するための標的送達を確実にします。喘息患者の急増と効果的な管理ソリューションの必要性は、ヘルスケアプロバイダーが患者数の増加をサポートする革新的な方法を模索し、呼吸器ケアにおけるこれらの治療デバイスの重要性を強調しているため、市場の成長を促進しています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

COPDおよび喘息用デバイス市場規模：製品別& CAGR（2025-2032）

• 市場概要
• 吸入器
  • 薬剤粉末吸入器（DPI）
  • 定量噴霧式吸入器（MDI）
  • ソフトミスト吸入器
• ネブライザー
  • コンプレッサーネブライザー
  • 超音波ネブライザー
  • メッシュネブライザー

COPDおよび喘息用デバイス市場規模：適応症別& CAGR（2025-2032）

• 市場概要
• 喘息
• 慢性閉塞性肺疾患

COPDおよび喘息用デバイス市場規模：流通チャネル別& CAGR（2025-2032）

• 市場概要
• 小売薬局
• 病院
• オンライン薬局

COPDおよび喘息用デバイス市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• AstraZeneca Plc.（United Kingdom）
• GlaxoSmithKline Plc.（United Kingdom）
• Merck & Co., Inc.（United States）
• Novartis AG（Switzerland）
• 3M Company（United States）
• Baxter International Inc.（United States）
• ResMed Inc.（United States）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Cipla Ltd.（India）
• Omron Healthcare, Inc.（Japan）
• Invacare Corporation（United States）
• Masimo Corporation（United States）
• Nihon Kohden Corporation（Japan）
• Getinge AB（Sweden）
• Smiths Medical（United Kingdom）
• Allied Healthcare Products, Inc.（United States）
• Aerogen Ltd.（Ireland）
• PARI Medical Holding GmbH（Germany）

結論と推奨事項

Global COPD and Asthma Devices Market size was valued at USD 48.78 billion in 2023 and is poised to grow from USD 51.17 billion in 2024 to USD 75.03 billion by 2032, growing at a CAGR of 4.9% during the forecast period (2025-2032).

The market for pulmonary medication delivery devices is on the rise, driven by the increasing prevalence of chronic obstructive pulmonary disease (COPD) and asthma, as well as technological advancements and a growing elderly population. COPD, characterized by airflow blockage and symptoms like shortness of breath and chronic cough, and asthma, marked by compromised airway function and respiratory distress, necessitate effective inhalation therapies. These devices transform drug solutions into aerosolized particles, ensuring targeted delivery for managing these chronic conditions. The surge in asthma cases and the need for effective management solutions are propelling market growth, as healthcare providers seek innovative ways to support a rising patient population, underlining the importance of these therapeutic devices in respiratory care.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Copd And Asthma Devices market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global COPD And Asthma Devices Market Segmental Analysis

Global COPD and Asthma Devices Market is segmented by Product, Indication, Distribution Channel and region. Based on Product, the market is segmented into Inhalers and Nebulizers. Based on Indication, the market is segmented into Asthma and COPD. Based on Distribution Channel, the market is segmented into Retail Pharmacies, Hospitals and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global COPD And Asthma Devices Market

The global market for COPD and asthma devices is driven by the increasing incidence of various respiratory conditions such as COPD, asthma, and emphysema. There is an escalating demand for effective short-term treatments and rescue medications, particularly during sudden asthma attacks. Furthermore, government initiatives aimed at enhancing awareness of COPD and asthma symptoms, alongside manufacturers' efforts to innovate portable inhalation devices, are expected to contribute to market growth. As respiratory illnesses lead to significant health complications, the advancement of technology in inhalation devices plays a crucial role in addressing these challenges, facilitating both immediate relief and long-term management solutions for affected individuals.

Restraints in the Global COPD And Asthma Devices Market

The global market for COPD and asthma devices faces several restraints that may hinder its growth. Significant factors include the high cost associated with various inhalation devices and treatments, which can limit accessibility for patients. Environmental concerns regarding metered dose inhalers (MDI) also pose challenges. Furthermore, intense price competition among manufacturers can affect profit margins, while declining material quality may compromise the effectiveness of devices. Limited reimbursement options additionally exacerbate the situation, along with the patent expirations of highly profitable medications, creating hurdles for the sustained expansion of the market.

Market Trends of the Global COPD And Asthma Devices Market

The global COPD and asthma devices market is experiencing a significant shift towards digital inhalers, presenting substantial opportunities for clinical pharmacy. These innovative devices not only enable precise delivery of medication directly to the lungs, minimizing systemic side effects, but they also address persistent challenges in treatment, such as poor adherence and improper usage. As healthcare providers increasingly recognize the importance of patient compliance in managing chronic respiratory conditions, digital inhalers equipped with adherence tracking and user-friendly interfaces are gaining traction. This trend is likely to enhance treatment outcomes, reduce exacerbations, and drive market growth as patients seek more effective, technology-enabled management solutions for COPD and asthma.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global COPD and Asthma Devices Market Size by Product & CAGR (2025-2032)

• Market Overview
• Inhalers
  • Drug Powdered Inhalers (DPIs)
  • Metered Dose Inhalers (MDIs)
  • Soft Mist Inhalers
• Nebulizers
  • Compressor Nebulizers
  • Ultrasonic Nebulizers
  • Mesh Nebulizers

Global COPD and Asthma Devices Market Size by Indication & CAGR (2025-2032)

• Market Overview
• Asthma
• COPD

Global COPD and Asthma Devices Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Retail Pharmacies
• Hospitals
• Online Pharmacies

Global COPD and Asthma Devices Market Size & CAGR (2025-2032)

• North America (Product, Indication, Distribution Channel)
  • US
  • Canada
• Europe (Product, Indication, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Indication, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Indication, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Indication, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AstraZeneca Plc. (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline Plc. (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• 3M Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ResMed Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Omron Healthcare, Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Invacare Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Masimo Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nihon Kohden Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Getinge AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Smiths Medical (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allied Healthcare Products, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aerogen Ltd. (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PARI Medical Holding GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations